trending Market Intelligence /marketintelligence/en/news-insights/trending/ox5uopk2nu0a2slbfueika2 content esgSubNav
In This List

Acorda Therapeutics chief technology officer to resign

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Acorda Therapeutics chief technology officer to resign

Acorda Therapeutics Inc. said Rick Batycky is leaving as the company's chief technology officer, effective Aug. 20, to be the CEO of a privately held, venture-backed biotechnology company.

David Lawrence, chief of business operations, will take over the position for Acorda's Chelsea, Mass.-based manufacturing facility, which produces Inbrija, a drug indicated to treat symptoms of so-called off periods — times when the effects of a medication wears off — in Parkinson's disease. He will also handle the external manufacturing of Ampyra, a medication to help improve walking in adults with multiple sclerosis.

In addition, Chief Medical Officer Burkhard Blank will lead the company's pharmaceutical development and technical operations team.

Ardsley, N.Y.-based Acorda Therapeutics is a biopharmaceutical company that develops therapies to restore function and improve the lives of people with neurological disorders.